Business/Financial News
Wall Street Beat | Earnings Reports | Funding Roundup | Mergers & Acquisitions | Initial Public Offerings | Legal News
R&D expenses clip Thoratec’s profits, shares slide more than 6%
Aesthetics: Solta prices $15M offering as acquisition charges, losses swell in 2nd quarter
Solta Medical (NSDQ:SLTM) released pricing on a $15 million public offering intended to raise funds for general corporate purposes after the aesthetics devices maker incurred substantial charges during its 2nd quarter.
Layoffs: Hologic confirms cuts following $3.7B Gen-Probe merger
Abiomed posts record Q1 sales, earnings, shares slide anyway
Wall Street once again proved a fickle friend to Abiomed (NSDQ:ABMD), which posted record sales and earnings numbers for its fiscal 1st quarter today but still saw shares slide by nearly 2%.
Unimpressed, investors on The Street sent ABMD shares down 1.6% to $22.61 as of about 3 p.m. today, leaving at least 1 analyst baffled.
Johnson & Johnson to settle derivatives lawsuits
Johnson & Johnson (NYSE:JNJ) said it’s reached agreements to settle a trio of derivatives lawsuits filed by shareholders seeking to reform the healthcare conglomerate after a spate of damaging recalls across its product portfolio.
Hologic closes $4B Gen-Probe buyout | Wall Street Beat
MassDevice.com +3 | The top 3 med-tech stories for August 1, 2012
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Earnings: Allergan sheds poor lap-band sales, stays pretty in Q2
Edwards Lifesciences slides, rebounds on negative heart valve study
UPDATED August 1, 2012 with comments from Edwards Lifesciences re. Dr. Martin Leon
Private Equity: Chicago PE firm looking to spend new $750M fund in healthcare, lifesciences
Strategic private equity firm Water Street Healthcare Partners is looking to spend its newly raised $750 million fund in healthcare and lifesciences, $50 million to $500 million at a time.